Refine by
Cardiovascular Devices Articles & Analysis
36 news found
Known for their extraordinarily antiparasitic, antiplasmodial, anticorrosive, antioxidative, antibacterial, anti-HIV, and insecticidal activities, alkaloids have found wonderful use in the pharmaceutical and medicinal filed as well as the human food and drink industry. To cater to the growing market demand for such type of chemicals, Alfa Chemistry recently announced a decision to open a new ...
Our latest publication in Cardiovascular Engineering and Technology showcases the feasibility and functionality of our VCAST technology, a patented, AI-based medical system developed for non-invasive, clinical quantitative and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis. Using a ...
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
ByBayer AG
Women’s health platform Skrinings.lv announced today that it has partnered with multinational pharmaceutical company Gedeon Richter to launch a completely private educational platform that empowers people to make informed decisions about contraception and other birth control options. In the first two months of operations, more than 1,700 women across Northern and Western Europe have taken ...
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for BCDA-04, a proprietary allogeneic mesenchymal cell (MSC) population that is Neurokinin-1 receptor positive ...
– February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). ...
Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
The distinctive design allows it to be used with other devices. First introduced in Japan, the Lacrosse NSE ALPHA is now available in over 30 countries throughout Asia-Pacific, India, Middle East, Europe and Latin America, and is being very well received, with hundreds of thousands of units sold. “The catheter is the first platform to score plaque, crack calcium and ...
Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C ...
EBR Systems’ WiSE™ CRT System is world’s first and only wireless endocardial (inside the heart) left ventricle pacing system for heart failure EBR’s AU$110m ASX initial public offering today was strongly supported by new and existing institutional shareholders The new capital funds the completion of pivotal study, targeting FDA submission for approval in 2023 followed ...
Prior to joining Magnolia Medical, Bishop served as Vice President of Operations and R&D for Vascular Dynamics, an emerging growth medical technology company focused on innovative implantable devices to address the unmet need for patients with uncontrolled hypertension. ...
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. ...
This Series B financing round includes € 25 million from the cardiovascular-focused medical device platform company MitrAssist Holdings Limited accompanied by an additional € 4 million from the returning investor Maurizio Group. AdjuCor is developing an implantable heart assist device that, contrary to all existing heart assist ...
Their vast experience and expertise in cardiovascular will serve Elucid well as we continue to advance and commercialize our ...
ByElucid
– April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. ...
The Report’s list recognizes the most accomplished executives in the healthcare technology, whose leadership has been critical in developing industry leading medical devices, next generation software platforms, cutting-edge drugs and therapeutics, and advanced diagnostics, among other technologies. “This is a recognition for the whole Xeltis team, whose intense ...
– March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology. ...
– January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces the successful completion of the first remote robotic-assisted coronary angioplasty in Europe. The procedure was carried out by Prof. Eric Durand and Prof. Rémi Sabatier at the Rouen Medical Training Center and Caen University Hospital in ...
ByRobocath